For questions regarding press and media, contact:
Skip Irvine, Director, Global Therapeutic Franchise Communications
267-305-5397

Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study - 03/30/08

Results from ENHANCE Study - 03/30/08

Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial – 01/25/08

ENHANCE Chronology – 01/25/08

Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial – 01/14/08

Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial – 11/19/07

Product Information and Patient Information for VYTORIN^® (ezetimibe/simvastatin)

Product Information and Patient Information for ZETIA^® (ezetimibe)

To view PDF documents, you must have Adobe Reader installed on your computer.

This site is intended only for residents of the United States, its territories, and Puerto Rico.

VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. Other brands listed are the trademarks of their respective owners and are not trademarks of MSP Singapore Company, LLC.

Copyright © Merck/Schering-Plough Pharmaceuticals, 2008.
All rights reserved.